Dr. Jayesh R. Kamath, MD
Psychiatry (Psychiatry Physician)
- Medicare participating
At a glance
- Years since graduation
- 32
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 44
Licensed in Connecticut since 2004, according to the Connecticut Department of Public Health. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Psychiatry Physician primary
CT license 042994 (first issued 2004; active in renewal)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- John Dempsey Hospital of the University of Connect Farmington, CT
Medical groups
- University of Connecticut Health Center (639 clinicians)
- State of Connecticut (260 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 44
- Services billed
- 146
- Patients’ average age
- 66
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 20-29 minutes | 24 | 12 |
| Established patient office or other outpatient visit, 30-39 minutes | 17 | 11 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 2 companies reported 18 payments worth $7,814 in total to this clinician.
| Janssen Pharmaceuticals, Inc | $5,040 |
|---|---|
| Neurocrine Biosciences, Inc. | $2,774 |
| Consulting Fee | $5,040 |
|---|---|
| Travel and Lodging | $2,131 |
| Food and Beverage | $643 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Janssen Pharmaceuticals, Inc Jan 3, 2025 | Consulting Fee SPRAVATO · Neuroscience | $5,040 |
| Neurocrine Biosciences, Inc. Apr 9, 2025 | Travel and Lodging travel to San Diego, CA · in-kind | $814 |
| Neurocrine Biosciences, Inc. Apr 9, 2025 | Travel and Lodging travel to San Diego, CA · in-kind | $326 |
| Neurocrine Biosciences, Inc. Apr 10, 2025 | Travel and Lodging travel to San Diego, CA · in-kind | $292 |
| Neurocrine Biosciences, Inc. Apr 11, 2025 | Travel and Lodging travel to San Diego, CA · in-kind | $292 |
| Neurocrine Biosciences, Inc. May 6, 2025 | Travel and Lodging travel to San Diego, CA · in-kind | $232 |
| Neurocrine Biosciences, Inc. Apr 9, 2025 | Travel and Lodging travel to San Diego, CA · in-kind | $175 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 6 industry-funded studies in 2025, from 2 companies. The companies reported $152,784 in research payments for these studies, mostly to the institutions running them.
- A Two-Part Multicenter, Double-Blind, Randomized Placebo-Controlled Study to Evaluate Efficacy and Safety and the Maintenance of Effect of 20-mg Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderl…
Janssen Research & Development, LLC - A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of ITI-1284 as an Adjunctive Treatment in Patients With Generalized Anxiety Disorder Who Have an Inade…
Iti, Inc. (d/b/a Intra-cellular Therapies, Inc.) - A Study of Aticaprant in Adult and Elderly Participants With Major Depressive Disorder (MDD) (VENTURA-LT)
Janssen Research & Development, LLC - A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of Aticaprant 10 mg and 5 mg as Adjunctive Therapy in Adult Participants with Major Depressive Disord…
Janssen Research & Development, LLC - A Two-Part Multicenter, Double-Blind, Randomized Placebo-Controlled Study to Evaluate Efficacy and Safety and the Maintenance of Effect of 20-mg Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderl…
Janssen Research & Development, LLC - ITI-007-505
Iti, Inc. (d/b/a Intra-cellular Therapies, Inc.)
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.